Alice P. Chen

National Institutes of Health

Full Professor(heuristic)

PARP inhibition in cancer therapy · Oncology

h-index67

i10-index220

Publications760

Citations19,188

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 97

Abstract CT259: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial (RARE 3): Tiragolumab + Atezolizumab
Cancer Research · 2026-04-17
Abstract 1664: Novel GPC3-targeting antibody-drug conjugate using novel payload or dual payloads to treat hepatocellular carcinoma and non-small-cell lung cancer
Cancer Research · 2026-04-03
Abstract 4904: Reprogramming of the non-pathogenic E. coli surface architecture to create next-generation immune engagers for potent cancer therapies
Cancer Research · 2026-04-03
Abstract 1662: GSPT1 degrader antibody conjugate, BLB-201, for the treatment of high-risk acute myeloid leukemia
Cancer Research · 2026-04-03
Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials
Annals of Surgical Oncology · 2026-01-16 · 2 citations
Supplementary Figure 3 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Data from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Table 2 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Table 3 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Data 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Figure 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Clinical benefits of selumetinib in adults with neurofibromatosis type 1 – Authors' reply
The Lancet · 2025-12-01
Supplementary Table 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Figure 2 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
2025-12-01
Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
2025-11-25
Perceptions of Sickle Cell Disease in Sierra Leone
Global Journal of Health Science · 2025-11-20 · 1 citations
Editorial: Case reports in tumor genomics and ctDNA in precision medicine
Frontiers in Medicine · 2025-11-14
Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity
Blood · 2025-11-03 · 1 citations
Assessing Pediatric Endodontic Referrals to University-Based Clinics: A Retrospective Chart Review
Dentistry Journal · 2025-11-03
Abstract A016: cfDNA fragmentome predicts cancer treatment response similarly to mutant allele fraction
Molecular Cancer Therapeutics · 2025-10-22

Open author page on OpenAlex →